Genetic Technologies (Genetic Technologies) Change In Receivables : $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Genetic Technologies Change In Receivables?

Genetic Technologies's change in receivables for the quarter that ended in Dec. 2023 was $0.00 Mil. It means Genetic Technologies's Accounts Receivable stayed the same from Sep. 2023 to Dec. 2023 .

Genetic Technologies's change in receivables for the fiscal year that ended in Jun. 2023 was $0.00 Mil. It means Genetic Technologies's Accounts Receivable stayed the same from Jun. 2022 to Jun. 2023 .

Genetic Technologies's Accounts Receivable for the quarter that ended in Dec. 2023 was $0.75 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Genetic Technologies's liquidation value for the three months ended in Dec. 2023 was $0.74 Mil.

Genetic Technologies Change In Receivables Historical Data

The historical data trend for Genetic Technologies's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Technologies Change In Receivables Chart

Genetic Technologies Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Change In Receivables

Get a 7-Day Free Trial

Genetic Technologies Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Genetic Technologies Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Genetic Technologies (NAS:GENE) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Genetic Technologies's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.746	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Genetic Technologies's accounts receivable are only considered to be worth 75% of book value:

Genetic Technologies's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	2.496	-	2.446	+	0.75 * 0.746	+	0.5 * 0.266
=	0.74

Genetic Technologies Change In Receivables Related Terms

Thank you for viewing the detailed overview of Genetic Technologies's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Genetic Technologies (Genetic Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (NAS:GENE) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

DU8:Germany GTG:Australia

Address

60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065

Website

https://www.gtglabs.com

Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.